As previously reported, Wedbush analyst Laura Chico downgraded Chinook Therapeutics (KDNY) to Neutral from Outperform with a $42 price target, given approaching acquisition. Most notable in the Q2 update, Chinook anticipates the forthcoming acquisition by Novartis (NVS) should close in the next week. Recall, Novartis made a bid in June to acquire Chinook for a total consideration of $4B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KDNY:
- Chinook Therapeutics downgraded to Neutral from Outperform at Wedbush
- Chinook Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
- Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
- Chinook Therapeutics presents data from CHK-336 Phase 1 trial